Nothing Special   »   [go: up one dir, main page]

HK1210794A1 - Antibody and protein formulations - Google Patents

Antibody and protein formulations

Info

Publication number
HK1210794A1
HK1210794A1 HK15111675.2A HK15111675A HK1210794A1 HK 1210794 A1 HK1210794 A1 HK 1210794A1 HK 15111675 A HK15111675 A HK 15111675A HK 1210794 A1 HK1210794 A1 HK 1210794A1
Authority
HK
Hong Kong
Prior art keywords
antibody
protein formulations
formulations
protein
Prior art date
Application number
HK15111675.2A
Other languages
English (en)
Chinese (zh)
Inventor
Xinghang Ma
Jun Xiang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/601,598 external-priority patent/US8613919B1/en
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of HK1210794A1 publication Critical patent/HK1210794A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK15111675.2A 2012-08-31 2015-11-27 Antibody and protein formulations HK1210794A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/601,598 US8613919B1 (en) 2012-08-31 2012-08-31 High concentration antibody and protein formulations
US13/843,780 US9592297B2 (en) 2012-08-31 2013-03-15 Antibody and protein formulations
PCT/US2013/056970 WO2014036071A1 (en) 2012-08-31 2013-08-28 Antibody and protein formulations

Publications (1)

Publication Number Publication Date
HK1210794A1 true HK1210794A1 (en) 2016-05-06

Family

ID=49162239

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111675.2A HK1210794A1 (en) 2012-08-31 2015-11-27 Antibody and protein formulations

Country Status (26)

Country Link
US (7) US9592297B2 (es)
EP (3) EP2890718A1 (es)
JP (3) JP6462567B2 (es)
CN (2) CN104684933B (es)
AR (2) AR092388A1 (es)
AU (3) AU2013308902B2 (es)
BR (1) BR112015003838A2 (es)
CA (2) CA3129277A1 (es)
CY (1) CY1121989T1 (es)
DK (1) DK3117837T3 (es)
ES (1) ES2741575T3 (es)
HK (1) HK1210794A1 (es)
HR (1) HRP20191299T1 (es)
HU (1) HUE045652T2 (es)
IL (6) IL286784B (es)
LT (1) LT3117837T (es)
MX (2) MX369653B (es)
PL (1) PL3117837T3 (es)
PT (1) PT3117837T (es)
RS (1) RS59221B1 (es)
RU (2) RU2678097C2 (es)
SG (2) SG10201708215YA (es)
SI (1) SI3117837T1 (es)
TW (4) TW201414496A (es)
UY (1) UY34995A (es)
WO (1) WO2014036071A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2642512T3 (es) 2010-03-01 2017-11-16 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
EA034214B1 (ru) * 2011-04-01 2020-01-17 Байер Хелфкеа Ллк Выделенное моноклональное антитело или его антигенсвязывающий фрагмент, который связывается с эпитопом ингибитора пути тканевого фактора человека, содержащая его фармацевтическая композиция, способ применения этой композиции и кодирующая антитело молекула нуклеиновой кислоты
AT512589B1 (de) * 2012-03-12 2014-06-15 Zizala Lichtsysteme Gmbh Lichtleitelement für einen Laser-Fahrzeugscheinwerfer sowie Fahrzeugscheinwerfer
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
IL312865A (en) 2013-09-11 2024-07-01 Eagle Biologics Inc Liquid protein formulations containing viscosity reducing agents
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
MX2017004196A (es) 2014-10-01 2017-07-19 Medimmune Ltd Anticuerpos contra ticagrelor y metodos de uso.
CA2962768C (en) 2014-10-01 2023-10-10 Alyssa M. Larson Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
KR102068915B1 (ko) 2015-08-19 2020-01-22 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
JP6720293B2 (ja) 2015-08-19 2020-07-08 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 安定な抗ｉｆｎａｒ１製剤
KR20200035496A (ko) * 2015-09-22 2020-04-03 화이자 인코포레이티드 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형
EP3443346B1 (en) * 2016-04-13 2023-08-30 Medimmune, LLC Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
HUE066142T2 (hu) 2016-06-30 2024-07-28 Celltrion Inc Stabil folyékony gyógyszerészeti készítmény
US10279048B2 (en) 2016-07-13 2019-05-07 Reform Biologics, Llc Stabilizing excipients for therapeutic protein formulations
WO2018050870A1 (en) 2016-09-16 2018-03-22 Leukocare Ag A novel method for stabilization of a biopharmaceutical drug product during processing
UA128200C2 (uk) * 2016-12-23 2024-05-08 Серум Інстітьют Оф Індія Прайвет Лімітед Удосконалені способи підвищення продуктивності антитіл у культурах клітин ссавців і зведення до мінімуму агрегації у процесах виділення і очищення, одержання композицій та стабільні композиції антитіл, одержані цими способами
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
BR112020019065A2 (pt) * 2018-03-23 2020-12-29 AbbVie Deutschland GmbH & Co. KG Formulações de anticorpo anti-tau aquosas estáveis
CA3099551A1 (en) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
MX2021000028A (es) * 2018-07-05 2021-03-09 Bayer Ag Metodo para la produccion de granulos liofilizados que comprenden un anticuerpo anti-factor xia (fxia) de la coagulacion.
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN113056482A (zh) * 2018-10-18 2021-06-29 默沙东公司 抗rsv抗体的制剂及其使用方法
CN111346225A (zh) * 2018-12-21 2020-06-30 上海张江生物技术有限公司 含有蛋白质的药物制剂
JP7266108B2 (ja) * 2019-02-18 2023-04-27 イーライ リリー アンド カンパニー 治療用抗体製剤
WO2020223565A1 (en) * 2019-05-01 2020-11-05 Corvidia Therapeutics, Inc. Anti-il-6 antibody formulation
CA3160806A1 (en) * 2019-11-13 2021-05-20 Pfizer Inc. Stable aqueous formulation containing anti-tfpi antibody _______
TW202404640A (zh) * 2022-07-27 2024-02-01 美商維埃拉生物股份有限公司 包含免疫球蛋白樣轉錄本７（ｉｌｔ７）結合蛋白之調配物

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1064396A (en) 1975-02-18 1979-10-16 Myer L. Coval Fractional precipitation of gamma globulin with polyethylene glycol
US4075193A (en) 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
EP0303746B2 (en) 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilization of growth promoting hormones
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4912861A (en) * 1988-04-11 1990-04-03 Huang Ing Chung Removable pressure-adjustable shock-absorbing cushion device with an inflation pump for sports goods
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
EP0417193B1 (en) 1988-05-27 1993-08-04 Centocor, Inc. Freeze-dried formulation for antibody products
JPH04504253A (ja) 1989-03-27 1992-07-30 セントカー・インコーポレーテツド ＩｇＭ抗体の安定化のための配合物
US5217954A (en) 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
JP2966592B2 (ja) 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
AU685784B2 (en) 1993-02-23 1998-01-29 Genentech Inc. Excipient stabilization of polypeptides treated with organic solvents
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
WO1997004801A1 (en) 1995-07-27 1997-02-13 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6686191B1 (en) 1995-09-22 2004-02-03 Bayer Healthcare Llc Preparation of virally inactivated intravenously injectable immune serum globulin
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
EP0876140B1 (de) 1996-01-25 2003-10-15 Schering Aktiengesellschaft Verbesserte kontrastmittenlösungen für die intravasale anwendung
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
DE59806877D1 (de) 1997-08-21 2003-02-13 Siemens Ag Verfahren zum übertragen von nutzdaten, die unterschiedlichen anwendungen zuordenbar sind
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
NZ529856A (en) 1999-10-04 2005-09-30 Chiron Corp Stabilized liquid polypeptide-containing pharmaceutical compositions
WO2001064241A1 (fr) 2000-02-29 2001-09-07 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees a long terme
PT1272211E (pt) 2000-04-07 2007-09-14 Signal Coordinating Therapy In Métodos e composições papa tratar neoplasmas
JP5490972B2 (ja) 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
AU2001277781A1 (en) 2000-08-11 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
EP1930024A3 (en) 2000-09-01 2008-08-06 Chugai Seiyaku Kabushiki Kaisha G-CSF solution formulations having long-term stability
ATE442862T2 (de) 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
AU2002335815A1 (en) 2001-10-16 2003-04-28 Rxkinetix, Inc. High-concentration protein formulations and method of manufacture
EP1441589B1 (en) 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
US20030138416A1 (en) 2001-12-03 2003-07-24 Jesper Lau Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
AU2002351353A1 (en) 2001-12-19 2003-09-02 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
EP2311489A3 (en) 2002-02-14 2013-08-21 Chugai Seiyaku Kabushiki Kaisha Formulation of antibody-containing solutions comprising a sugar as a stabilizer
MXPA04008215A (es) 2002-02-27 2004-11-26 Immunex Corp Formulacion polipeptidica.
AU2005254062B2 (en) 2002-04-11 2011-02-17 Medimmune, Llc High pressure spray-dry of bioactive materials
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
EP1551875A4 (en) 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
CN1703233A (zh) 2002-07-12 2005-11-30 米德列斯公司 防止蛋白氧化降解的方法和组合物
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
RU2338555C2 (ru) 2002-10-08 2008-11-20 Ринат Ньюросайенс Корп. Способы лечения послеоперационной боли введением антагониста фактора роста нервов и композиции, содержащие фактор роста нервов
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
PL215171B1 (pl) 2002-12-24 2013-10-31 Rinat Neuroscience Corp Przeciwcialo przeciw czynnikowi wzrostu nerwów (NGF) lub jego fragment, kompozycja farmaceutyczna, zestaw, sposób wytwarzania przeciwciala lub jego fragmentu, zastosowanie skutecznej ilosci antagonistycznego przeciwciala anty-NGF lub jego fragmentu, zastosowanie antagonistycznego przeciwciala anty-NGF lub jego fragmentu, izolowany polinukleotyd zawierajacy sekwencje nukleotydowa kodujaca przeciwcialo lub jego fragment, wektor oraz komórka gospodarza zawierajaca polinukleotyd
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
KR101208291B1 (ko) 2003-04-04 2012-12-05 노파르티스 아게 고농도 항체 및 단백질 제형
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
DK1648509T3 (da) 2003-07-15 2013-01-07 Amgen Inc Humane anti-NGF-neutraliserende antistoffer som selektive NGF-pathway-inhibitorer
PL1698640T5 (pl) 2003-10-01 2019-12-31 Kyowa Hakko Kirin Co., Ltd. Sposób stabilizacji przeciwciała i stabilizowany preparat przeciwciała w postaci roztworu
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
WO2005063291A1 (ja) 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US20060210557A1 (en) 2005-01-28 2006-09-21 Donna Luisi Stabilized liquid polypeptide formulations
CN103861102A (zh) 2005-03-08 2014-06-18 辉瑞产品公司 抗ctla-4 抗体组合物
TW200714290A (en) 2005-03-08 2007-04-16 Pharmacia & Upjohn Co Llc Anti-M-CSF antibody compositions having reduced levels of endotoxin
EP1871803B1 (en) * 2005-04-18 2013-02-20 Yeda Research And Development Company Limited Stabilized anti-hepatitis b (hbv) antibody formulations
KR20080025174A (ko) * 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
EP2264161A1 (en) 2005-07-02 2010-12-22 Arecor Limited Stable aqueous systems comprising proteins
AU2006278573A1 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
US7790679B2 (en) 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations
WO2007056847A1 (en) 2005-11-21 2007-05-24 Sanofi Pasteur Limited Stabilizing formulations for recombinant viruses
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
EP1988922A4 (en) 2006-02-03 2010-06-02 Medimmune Llc PROTEIN FORMULATIONS
DE102006005094A1 (de) 2006-02-04 2007-08-09 Degussa Gmbh Titandioxid und Polycarboxylatether enthaltende Dispersion
JP2009540015A (ja) 2006-06-14 2009-11-19 イムクローン・リミテッド・ライアビリティ・カンパニー 抗ｅｇｆｒ抗体の凍結乾燥製剤
EP2038306B1 (en) 2006-06-30 2014-12-03 Novo Nordisk A/S Anti-nkg2a antibodies and uses thereof
MX2009003542A (es) 2006-10-12 2009-04-15 Wyeth Corp Metodos y composiciones con opalescencia reducida.
CL2007003583A1 (es) 2006-12-11 2008-07-18 Hoffmann La Roche Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
WO2009077483A1 (en) 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
WO2008121616A2 (en) 2007-03-30 2008-10-09 Medimmune, Inc. Antibodies with decreased deamidation profiles
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
EP3461500A1 (en) 2007-06-14 2019-04-03 Biogen MA Inc. Natalizumab antibody formulations
WO2009002521A2 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
RS53551B1 (en) 2007-12-21 2015-02-27 F. Hoffmann La Roche Ag ANTIBODY FORMULATION
UA100255C2 (uk) 2007-12-28 2012-12-10 Біоінвент Інтернешенл Аб Фармацевтична композиція
EP2826791A3 (en) 2008-02-20 2015-07-29 Novo Nordisk A/S Humanized anti-C5aR antibodies
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
JP2011526591A (ja) 2008-06-30 2011-10-13 ノボ・ノルデイスク・エー／エス 抗ヒトインターロイキン−２０抗体
UA112050C2 (uk) 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
HUE036126T2 (hu) 2008-09-19 2018-06-28 Pfizer Stabil folyékony ellenanyag kiszerelés
AU2009319856A1 (en) 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010072691A1 (en) 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
BRPI1006519A2 (pt) 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
MX2011013722A (es) 2009-06-18 2012-05-08 Wyeth Llc Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
DK2473528T3 (en) 2009-09-03 2015-03-02 Ablynx Nv Stable formulations of polypeptides and uses thereof
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
EP2538973A2 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Stable antibody containing compositions
ES2642512T3 (es) 2010-03-01 2017-11-16 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
WO2011108452A1 (ja) * 2010-03-02 2011-09-09 Jnc株式会社 還元反応器
JP5730983B2 (ja) * 2010-03-19 2015-06-10 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉ阻害剤および使用方法
CA2800188A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
JP5918246B2 (ja) * 2010-10-06 2016-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤
EA034214B1 (ru) 2011-04-01 2020-01-17 Байер Хелфкеа Ллк Выделенное моноклональное антитело или его антигенсвязывающий фрагмент, который связывается с эпитопом ингибитора пути тканевого фактора человека, содержащая его фармацевтическая композиция, способ применения этой композиции и кодирующая антитело молекула нуклеиновой кислоты
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Also Published As

Publication number Publication date
IL286784A (en) 2021-10-31
EP3117837A1 (en) 2017-01-18
HRP20191299T1 (hr) 2019-10-18
CA2883095A1 (en) 2014-03-06
HUE045652T2 (hu) 2020-01-28
EP2890718A1 (en) 2015-07-08
PT3117837T (pt) 2019-08-26
TW201825116A (zh) 2018-07-16
JP2019048886A (ja) 2019-03-28
US20150209431A1 (en) 2015-07-30
EP3117837B1 (en) 2019-05-22
MX369653B (es) 2019-11-15
TW201927338A (zh) 2019-07-16
US20140065159A1 (en) 2014-03-06
WO2014036071A1 (en) 2014-03-06
PL3117837T3 (pl) 2020-02-28
AU2013308902A1 (en) 2015-03-12
CA2883095C (en) 2021-10-26
SI3117837T1 (sl) 2019-10-30
JP6462567B2 (ja) 2019-01-30
US20230190637A9 (en) 2023-06-22
AU2013308902B2 (en) 2018-04-12
AR092400A1 (es) 2015-04-22
TWI609697B (zh) 2018-01-01
US20180055940A1 (en) 2018-03-01
CY1121989T1 (el) 2020-10-14
EP3590536A1 (en) 2020-01-08
TW201424748A (zh) 2014-07-01
US9849181B2 (en) 2017-12-26
RU2678097C2 (ru) 2019-01-23
CA3129277A1 (en) 2014-03-06
US9592297B2 (en) 2017-03-14
US20140105892A1 (en) 2014-04-17
US20180028669A1 (en) 2018-02-01
IL265864A (en) 2019-06-30
JP2015528464A (ja) 2015-09-28
MX2015002411A (es) 2015-06-05
TW201414496A (zh) 2014-04-16
IL265865A (en) 2019-06-30
IL265864B (en) 2020-02-27
BR112015003838A2 (pt) 2017-07-04
AR092388A1 (es) 2015-04-22
IL237188A0 (en) 2015-04-30
RS59221B1 (sr) 2019-10-31
CN114392353A (zh) 2022-04-26
DK3117837T3 (da) 2019-08-19
US20150030591A1 (en) 2015-01-29
MX2019013670A (es) 2020-01-15
AU2018203320A1 (en) 2018-05-31
AU2018203320B2 (en) 2020-02-27
CN104684933B (zh) 2021-11-30
CN104684933A (zh) 2015-06-03
SG10201708215YA (en) 2017-11-29
JP2021059602A (ja) 2021-04-15
ES2741575T3 (es) 2020-02-11
LT3117837T (lt) 2019-09-25
AU2020200134A1 (en) 2020-01-30
IL294567A (en) 2022-09-01
RU2019100887A (ru) 2019-03-22
UY34995A (es) 2014-03-31
IL286784B (en) 2022-08-01
RU2019100887A3 (es) 2019-08-27
US20210077381A1 (en) 2021-03-18
RU2015111341A (ru) 2016-10-27
IL279237A (en) 2021-01-31
SG11201501116RA (en) 2015-04-29

Similar Documents

Publication Publication Date Title
IL286784A (en) Compositions of protein and antibody
HK1243344A1 (zh) 抗體製劑和方法
HK1210714A1 (en) Antibody formulations and uses thereof
HRP20190358T1 (hr) Antitijela protiv asic1 i njihova primjena
HK1207654A1 (en) Modified antibody regions and uses thereof
ZA201405554B (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EP2930189A4 (en) CHEMOKINE-CYTOKINE FUSION PROTEIN AND USE THEREOF
GB201208372D0 (en) Antibodies and uses thereof